The University of Chicago Header Logo

Connection

Mark Talamonti to Bevacizumab

This is a "connection" page, showing publications Mark Talamonti has written about Bevacizumab.
Connection Strength

0.205
  1. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):476-82.
    View in: PubMed
    Score: 0.086
  2. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. J Surg Oncol. 2010 Oct 01; 102(5):539-42.
    View in: PubMed
    Score: 0.083
  3. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.